Table 2.
Mainly clinical trial and targeted therapies in no first-line metastasic colorectal treatment.
| Study | Design | RR | p-value | Median PFS | p-value | Median OS | p-value |
|---|---|---|---|---|---|---|---|
| Eastern Coop. Oncology Group 3500 35 | Bevacizumab + FOLFOX vs. FOLFOX |
22.7 8.6 |
0.0001 | 7.3 4.7 |
0.0001 | 12.9 10.8 |
0.0011 |
| Hurwitz et al. 17 | Bevacizumab + FOLFIRI vs. FOLFIRI |
- - |
- | - - |
- | 25.1 22.2 |
- |
| EPIC study 36 | Cetuximab + FOLFIRI vs. FOLFIRI |
16.4 4.2 |
0.0001 | 4.0 2.6 |
0.0001 | 10.7 10.0 |
0.71 |
| Peeters et al. 38 | Panitumumab + FOLFIRI vs. FOLFIRI |
- - |
- | 5.9 3.9 |
0.004 | 14.5 12.5 |
0.12 |
| VELOUR study 39 | Aflibercept + FOLFIRI vs. FOLFIRI |
19.8 11.1 |
0.0001 | 6.90 4.67 |
0.0001 | 13.50 12.06 |
0.0032 |
| RAISE study 40 | Ramucirumab + FOLFIRI vs. FOLFIRI |
- - |
- | 5.7 4.5 |
0.0005 | 13.3 11.7 |
0.0219 |
RR: response rate (%). PFS: progression free-survival (months). OS: overall survival (months).